A retrospective study in patients with newly diagnosed cancer has identified an increased risk of cardiovascular (CV) abnormalities that are aggravated by cancer stage.
A retrospective study in patients with newly diagnosed cancer has identified an increased risk of cardiovascular (CV) abnormalities that are aggravated by cancer stage.
A cancer diagnosis can prove to be a source of significant stress for the patient—online stress management programs have been developed in an effort to lower the psychological stress in this population. One such study conducted in Europe, the results of which were presented at the annual meeting of the American Society of Clinical Oncology, found that participants experienced a significant improvement in their distress levels and anxiety and depression about the diagnosis also subsided.
To understand the early physiologic effects of such stress in the newly diagnosed population, researchers examined the Surveillance Epidemiology and End Results—Medicare linked database to populate information on patients who had a new primary diagnosis of breast, lung, prostate, colorectal, bladder, pancreatic, or gastric cancer or non-Hodgkin lymphoma between 2002 and 2011. Matched controls without cancer were included in this study and the pairs were followed through 2012.
The primary outcomes of interest were myocardial infarction (MI) and ischemic stroke, both defined under the umbrella of arterial thromboembolism (to assist with collecting diagnostic code data).
Of the 279,719 matched pairs that were included in the analysis, the 6-month cumulative incidence of arterial thromboembolism was 4.7% in patients with cancer (95% CI, 4.6%-4.8%), compared with 2.2% (95% CI, 2.1%-2.2%) in control patients (hazard ratio [HR], 2.2; 95% CI, 2.1-2.3). Specifically, patients with cancer were more than twice as likely to suffer an MI and about twice as likely to suffer an ischemic stroke compared with their matched control. The 6-month cumulative incidence of MI was 2.0% (95% CI, 1.9%-2.0%) in the patient compared with 0.7% (95% CI, 0.6%-0.7%) in control patients (HR, 2.9; 95% CI, 2.8-3.1). The incidence of ischemic stroke was 3.0% (95% CI, 2.9%-3.1%) in patients and 1.6% (95% CI, 1.6%-1.7%) in controls (HR, 1.9; 95% CI, 1.8-2.0).
The authors also note that their analysis found that cancer stage was associated with an increased risk of these events in the patients, but the risk usually resolved within a year. Additionally, the highest risk was observed in patients with lung, gastric, and pancreatic cancers—these 3 cancer types have some of the poorest 5-year survival rates in the United States.
The authors discuss the need for a CV intervention, such as an antithrombotic or statin, to prevent CV progression in these patients, and recommend designing clinical trials to answer these questions.
The study has been published in the Journal of the American College of Cardiology.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More